GlaxoSmithKline begins phase 3 trial for coronary heart disease treatment
LONDON GlaxoSmithKline has started its first phase 3 clinical trial to determine the efficacy of the investigational Lp-PLA2 inhibitor darapladib, for adults with chronic coronary heart disease, GSK announced Thursday.
The Stabilization of Atherosclerotic Plaque By Initiation of Darapladib Therapy, or STABILITY study, will include more than 15,000 patients from 39 studies.
“Despite major advances in medical treatment, coronary heart disease remains the leading cause of death worldwide, and new approaches are needed to help reduce this burden to patients and society,” GlaxoSmithKline senior vice president for drug discovery Patrick Vallance said in a statement. “GSJ is initiating the large STABILITY trial with darapladib as part of a phase 3 program to determine if this novel medication could improve people?s lives by reducing the risk of cardiovascular events.”
Aurora to support Concordia University School of Pharmacy
MEQUON, Wis. Milwaukee-based Aurora Health Care will provide program support for Concordia University Wisconsin’s upcoming School of Pharmacy, Concordia officials announced Wednesday.
“It is important that we extend our resources to help ensure there are more opportunities to educate and train pharmacists in Wisconsin,” Aurora president and chief executive officer Nick Turkal said in a statement. “We have a longstanding commitment to find solutions to the challenges of health care, including the need to fill those positions where there are workforce shortages.”
One part of Aurora’s support involves letting Concordia pharmacy students work at Aurora pharmacies while its pharmacists serve as instructors at the school.
“We are excited with the news that Aurora Health Care will be partnering with us,” Concordia School of Pharmacy executive dean Curt Gielow said.
Concordia has raised $3 million of the $20 million it needs to build the pharmacy school by the 2011-2012 academic year, including $17 million to construct the building, Gielow said. The school will accept 50 to 75 students per class and train practitioner pharmacists to work in urban and rural areas.
The academic program will include a standard “2+4” program, comprising a two-year pre-pharmacy program and a four-year professional program, as well as a four-year bachelor of science degree program in pharmaceutical sciences.
Milwaukee is one of the largest cities in the country without a local pharmacy school.
FDA grants waivers to Abaxis for point-of-care analyzers
UNION CITY, Calif. The Food and Drug Administration has given blood-analysis system manufacturer Abaxis a waived status for two analytes, creatine kinase and phosphorus, when used by healthcare professionals with the Piccolo and Piccolo Xpress point-of-care analyzers, Abaxis said last week.
The company said Thursday that as a result of the waived status, healthcare professionals have better access to the Renal Function and MetLyte 8 panels and can conduct this testing at the point-of-care under a certificate of waiver.
“The waiver of these two panels bolsters our already comprehensive offering to healthcare professionals, enabling them to conduct important testing at the point of care in order to manage patients in real time,” Abaxis chairman and chief executive officer Clint Severson said in a statement. “We believe rapid and accurate diagnostic testing can lead to improved patient care while reducing some of the administrative burden healthcare practices face on a daily basis.”
The panels are respectively used to determine renal function status and to assess several metabolic conditions across several medical specialties, including pediatrics and cardiology.